(Q36725234)

15 August 2017

1 reference

title

A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease (English)

1 reference

15 August 2017

0 references

Frederick Schmitt

1

1 reference

15 August 2017

Melody Ryan

series ordinal

2

1 reference

15 August 2017

Gregory Cooper

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

135-141

1 reference

Alzheimer's disease is a synaptic failure

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Defining molecular targets to prevent Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Glutamate transmission and toxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Neuroprotective effect of memantine demonstrated in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

NMDA receptors and voltage-dependent calcium channels mediate different aspects of acquisition and retention of a spatial memory task

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Long-term depression of NMDA receptor-mediated synaptic transmission is dependent on activation of metabotropic glutamate receptors and is altered to long-term potentiation by low intracellular calcium buffering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

A systematic review of assessment and treatment of moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Evaluation of memantine for neuroprotection in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

PET studies of 18F-memantine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Influence of urine pH and urinary flow on the renal excretion of memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Pharmacokinetic study of memantine in healthy and renally impaired subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.1.135

21 January 2018

Identifiers

DOI

10.1517/17425255.3.1.135

1 reference

15 August 2017

1 reference